The proposal of the Board regarding dividend

The proposal of the Board regarding dividend

In accordance with the company's dividend policy, whereby it is proposed that
approximately 50 percent of net income for the year after tax be paid as a
regular dividend, the Board of Q-Med AB has decided to propose to the Annual
General Meeting a dividend of 1.50 SEK per share. Net income after tax for 2007
amounted to 315 (212) MSEK, of which it is proposed that 149 MSEK be paid as a
dividend.

Queries should be addressed to:
Madelene Sandgren, Director Investor Relations and Corporate Communications 
Tel: +46 (0) 70 974 9015 

Q-Med AB is a rapidly growing and profitable biotechnology/medical device
company. The company develops, manufactures, markets, and sells primarily
medical implants. The majority of the products are based on the company's
patented technology, NASHA™, for the production of stabilized non-animal
hyaluronic acid. The product portfolio today contains: Restylane® for filling
lines and folds, contouring and creating volume in the face, Macrolane™ for body
contouring, Durolane™ for the treatment of osteoarthritis of the hip and knee
joints, Deflux™ for the treatment of vesicoureteral reflux, VUR, (a malformation
of the urinary bladder) in children, and Solesta™ for the treatment of fecal
incontinence. Sales are made through the company's own subsidiaries or
distributors in over 70 countries. Q Med today has just over 700 coworkers, with
close to 500 at the company's head office and production facility in Uppsala,
Sweden. Q-Med AB is listed in the Mid Cap segment of the OMX Nordic Exchange in
Stockholm.


Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate
identity number 556258-6882.
Tel: +46(0)18-474 90 00. Fax: +46(0)18-474 90 01. E-mail: info@q-med.com. Web:
www.q-med.com.

In USA, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med Scandinavia,
Inc.